Project Grant R21AI191565
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$227K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, is funding research to investigate how Mycobacterium tuberculosis (MTB) infection triggers host cell death mechanisms. The $819,998 award to The Regents of the University of California, San Francisco (UCSF) aims to elucidate the regulatory roles of autophagy factors TAX1BP1 and optineurin in modulating MTB pathogenesis and host cell death...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The $820,246 award to the Albert Einstein College of Medicine will be used to investigate the roles of these secreted proteins in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $404,108 to the University of California, Davis (UC Davis) to identify genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) persister cells to survive antibiotic treatment. The award aims to apply genetic and proteomic approaches to uncover the core mechanisms driving MTB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...
This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Yale University to understand antibiotic tolerance in Mycobacterium tuberculosis (MTB). The key objectives are to: 1) Identify the subcellular environments and carbon sources associated with drug-tolerant MTB, and 2) Develop in vitro culture conditions mimicking these environments for future...